European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the ...

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD, or mild cognitive impairment due to ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

Jan 27 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Monday that its board has unanimously rejected Biogen’s (BIIB.O), opens new tab $469 million offer, stating it "significantly ...

Analysts viewed Biogen’s offer as a “cold and calculated” move to consolidate control of Zurzuvae, which is on track to earn around $100 million in annual sales. The companies currently split profits.

Mel Gibson has said he wants to help solve the problem of people leaving Hollywood as part of his role as one of President Donald Trump's "special envoys." Ahead of his inauguration, Trump named ...

John Gibson was ruled out by the team with an upper-body injury to begin the second period and was replaced by Lukas Dostal. It’s unclear exactly how the injury occurred, as Gibson played the ...

ANAHEIM, Calif. (AP) — Ducks goaltender John Gibson suffered an upper-body injury during the first period of Saturday night’s game against the Nashville Predators and was replaced between periods.